Pfizer PFE Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pfizer's finite-lived intangible assets, accumulated amortization?
- Pfizer (PFE) reported finite-lived intangible assets, accumulated amortization of $73.86B in Q1 2026.
- How has Pfizer's finite-lived intangible assets, accumulated amortization changed year-over-year?
- Pfizer's finite-lived intangible assets, accumulated amortization increased by 7.4% year-over-year, from $68.78B to $73.86B.
- What is the long-term trend for Pfizer's finite-lived intangible assets, accumulated amortization?
- Over 5 years (2020 to 2025), Pfizer's finite-lived intangible assets, accumulated amortization has grown at a 6.5% compound annual growth rate (CAGR), from $52.86B to $72.5B.